UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant
to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (date of earliest event reported): June 9, 2015
OMEROS CORPORATION
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Washington |
|
001-34475 |
|
91-1663741 |
(State or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(IRS Employer
Identification No.) |
201 Elliott Avenue West
Seattle, Washington 98119
(Address of principal executive offices, including zip code)
(206) 676-5000
(Registrants telephone number, including area code)
(Former name or former address, if changed since last report)
Check appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following
provisions:
¨ |
Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
¨ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
¨ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
¨ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Item 1.01 Entry into a Material Definitive Agreement.
On June 9, 2015, Omeros Corporation, or Omeros, entered into an exclusive licensing agreement, or the Agreement, with Fagron Compounding
Services, LLC, d/b/a Fagron Sterile Services, and JCB Laboratories, LLC, or collectively Fagron, a Food and Drug Administration-registered human drug outsourcing facility in Wichita, Kansas, under which Fagron will commercialize Omeros
PharmacoSurgery® product candidate, OMS103. OMS103 has been developed for use during arthroscopic procedures, including partial meniscectomy surgery. Pursuant to the Agreement, Omeros granted
Fagron an exclusive, royalty-free license to the OMS103 intellectual property, manufacturing information and clinical data to produce on a large scale registered basis and commercialize OMS103 in the United States.
Under the terms of the Agreement, upon commercialization, Omeros will receive payments representing a substantial majority share of gross
revenue from future OMS103 product sales within the United States, which revenue share will not be less than a minimum per unit amount. Additionally, Omeros is eligible to receive up to an aggregate total of $10 million in potential payments upon
the achievement of specific commercial milestones and as revenue-share enhancement on early sales. Fagron is obligated to meet performance diligence requirements including the commencement of commercial supply of OMS103 in 2015, to bear all sales
and marketing costs, and to meet annual sales volume minimums. Omeros will incur no further development costs, other than maintaining the licensed intellectual property, in connection with OMS103. The Agreement also contemplates potential
partnerships for additional products from Omeros PharmacoSurgery® platform.
Unless terminated earlier, the Agreement will continue until expiration of the last-to-expire of the patents in the licensed intellectual
property or as otherwise provided under the terms of the Agreement. Either party may terminate the Agreement earlier if the other party materially breaches the Agreement and does not cure the breach within a specified notice period, or upon the
other partys insolvency. Additionally, Omeros may terminate the Agreement earlier if Fagron does not meet its performance diligence requirements, in response to a negative action by a regulatory authority, or if Fagron opposes or challenges
any of the licensed patents for OMS103.
The foregoing description of certain terms of the Agreement is only a summary of its material
terms and does not purport to be complete. On June 16, 2015, Omeros issued a press release announcing the Agreement. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 1.02 Termination of a Material Definitive Agreement
In anticipation of its discontinuance of its development of OMS103 and subsequent entry of the Agreement with Fagron, on June 9, 2015,
Omeros delivered to Hospira Worldwide Inc., or Hospira, a notice terminating the parties Commercial Supply Agreement, effective October 9, 2007, or the Supply Agreement, for the commercial supply of OMS103HP-S. Under the Supply Agreement,
Hospira had agreed to provide, and Omeros had agreed to purchase, a minimum quantity of Omeros commercial supply needs of OMS103HP-S following approval for marketing. The termination of the Supply Agreement was effective on June 9, 2015.
Omeros does not expect to have any further obligations under this agreement.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
|
|
|
Exhibit Number |
|
Exhibit Description |
|
|
99.1 |
|
Press Release dated June 16, 2015, regarding Omeros entry into an exclusive licensing agreement. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
OMEROS CORPORATION |
|
|
By: |
|
/s/ Gregory A. Demopulos |
|
|
Gregory A. Demopulos, M.D. |
|
|
President, Chief Executive Officer and |
|
|
Chairman of the Board of Directors |
Date: June 16, 2015
EXHIBIT INDEX
|
|
|
Exhibit Number |
|
Description |
|
|
99.1 |
|
Press Release dated June 16, 2015, regarding Omeros entry into an exclusive licensing agreement. |
Exhibit 99.1
Omeros Announces Exclusive License Agreement for Omeros Arthroscopic Product OMS103
U.S. Sales to Begin This Year
SEATTLE, WA June 16, 2015 Omeros Corporation (NASDAQ: OMER), a biopharmaceutical company committed to discovering, developing and
commercializing small-molecule and protein therapeutics for both large-market as well as orphan indications, today announced that it has entered into an exclusive license agreement with affiliates of Fagron NV (EBR: FAGR) for the commercialization
of OMS103, Omeros product for arthroscopic surgery.
OMS103, added to standard irrigation solution used in arthroscopy, is Omeros proprietary
PharmacoSurgery® product designed to provide a multimodal approach to block preemptively the inflammatory cascade induced by arthroscopic surgical procedures. Nearly five million arthroscopic
procedures are projected to be performed in the U.S. in 2015.
Under the terms of the license agreement, Omeros granted Fagron an exclusive license to the
OMS103 intellectual property, manufacturing information, and clinical data in the United States. In exchange for the U.S. license, Fagron will pay Omeros a substantial majority share of the gross revenues generated from sales of OMS103 with Omeros
also receiving a minimum revenue per vial sold. In addition, Fagron will pay Omeros up to an aggregate total of $10 million in commercial milestones, some of which will be received by Omeros as revenue-share enhancement on early sales. Fagron is
obligated to meet performance diligence requirements including the commencement of sales of OMS103 in 2015, to bear all sales and marketing costs, and to meet annual sales volume minimums. In addition to transferring the manufacturing and clinical
information related to OMS103, Omeros is obligated to provide Fagron with introductions to arthroscopy thought leaders and assistance in understanding the therapeutic field as well as administration methods and to provide Fagron for 12 months with
reasonable access to Omeros personnel to respond to any queries regarding the clinical and manufacturing data. Omeros will incur no further development costs, other than maintaining the licensed intellectual property, in connection with OMS103. The
licensing agreement also contemplates potential partnerships for additional products from Omeros PharmacoSurgery platform.
Early
postoperative pain is predominantly inflammatory pain, and clinical evaluation of OMS103 demonstrated better pain reduction together with less narcotic usage and less frequent incidence of postoperative inflammatory problems, stated William E.
Garrett, Jr., M.D., Ph.D, professor of orthopaedic surgery and team physician at Duke University. There is increasing evidence that intraoperative joint inflammation is detrimental to the long-term health of the joint, and control of
postoperative pain and inflammation is critical to functional recovery in arthroscopy patients. Delivered intraoperatively, OMS103 provides an opportunity to inhibit inflammation and related problems before they begin and could become a key
component in managing arthroscopy patients.
We selected Fagron as our U.S. partner for OMS103 because of its robust sterile GMP manufacturing
and commercial capabilities, stated Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros. We believe that Fagron has the reach and expertise to bring OMS103 to orthopedic surgeons and their patients
nationwide.
In addition to its current U.S. sterile manufacturing capabilities, Fagron is scheduled to open later this year one of the
countrys largest FDA-registered 503B human drug outsourcing facilities, which is expected to utilize automation not yet seen in the nations sterile compounding industry. Together with Fagrons current operations, this
state-of-the-art outsourcing facility is planned for use to produce commercial supplies of OMS103.
About Omeros OMS103 Program
OMS103 is a proprietary combination of anti-inflammatory/analgesic active pharmaceutical ingredients (APIs), specifically amitriptyline, ketoprofen and
oxymetazoline, each with well-known safety and pharmacologic profiles. One of the major challenges facing orthopedic surgeons performing arthroscopic procedures is adequately controlling the local inflammatory response to surgical trauma,
particularly the inflammatory pain and swelling that are associated with detrimental effects on the long-term health of the joint. Added to standard irrigation solutions, OMS103 is delivered directly to the joint throughout arthroscopy, and is
designed to act simultaneously at multiple distinct targets to block preemptively the inflammatory cascade induced by arthroscopic surgery.
About
Omeros Corporation
Omeros is a biopharmaceutical company committed to discovering, developing and commercializing both small-molecule and protein
therapeutics for large-market as well as orphan indications targeting
inflammation, coagulopathies and disorders of the central nervous system. Derived from its proprietary PharmacoSurgery® platform, the
companys first drug product, Omidria® (phenylephrine and ketorolac injection) 1%/0.3%, has been approved by the FDA for use during cataract surgery or intraocular lens (IOL) replacement
to maintain pupil size by preventing intraoperative miosis (pupil constriction) and to reduce postoperative ocular pain. The marketing authorization application (MAA) for Omidria recently received a unanimous positive opinion from the European
Medicines agency, which forwarded the MAA to the European Commission for decision regarding final approval. Omeros has five clinical-stage development programs focused on: complement-related thrombotic microangiopathies; Huntingtons disease,
schizophrenia, and cognitive impairment; addictive and compulsive disorders; and preventing problems associated with surgical procedures. In addition, Omeros has a proprietary GPCR platform, which is making available an unprecedented number of new
GPCR drug targets and corresponding compounds to the pharmaceutical industry for drug development.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934, which are subject to the safe harbor created by those sections for such statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as
anticipate, believe, could, estimate, expect, goal, intend, look forward to, may, plan, potential,
predict, project, should, will, would and similar expressions. Forward-looking statements are based on beliefs and assumptions of Omeros management and on information available to
management only as of the date of this press release. Omeros actual results could differ materially from those anticipated in these forward-looking statements for many reasons, including, without limitation, risks associated with Omeros
collaboration with JCB contained in this press release, Omeros ability to obtain regulatory approval for its Marketing Authorization Application in the EU for the commercialization of
Omidria®, Omeros unproven preclinical and clinical development activities, regulatory oversight, product commercialization, intellectual property claims, competitive developments,
litigation, and the risks, uncertainties and other factors described under the heading Risk Factors in the Omeros Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on May 11, 2015. Given these risks,
uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and the company assumes no obligation to update these forward-looking statements, even if new information becomes available in the future.
Contact:
Omeros Corporation
Investor Relations
206.676.5000
ir@omeros.com
Omeros (NASDAQ:OMER)
Historical Stock Chart
From Mar 2024 to Apr 2024
Omeros (NASDAQ:OMER)
Historical Stock Chart
From Apr 2023 to Apr 2024